ConductScience.org, home

Paper39343752

Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.

Kim HJ and 1 other. Ann Dermatol, 2024. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives. Papers, record 39343752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39343752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.
PubMed
Journal
Ann Dermatol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
2.35, provisional
iCite
Revised in PubMed
2026-09-23
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kim HJHee Joohttps://orcid.org/0000-0003-1585-8184
2Werth VPVictoria Phttps://orcid.org/0000-0003-3030-5369

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 AR076766NIAMS NIH HHSUnited StatesR01AR076766PubMed

Source NIH RePORTER

Download CSV of grants

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125702838β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system.J Allergy Clin Immunol2015https://conductscience.org/library/papers/25702838PubMed
237331616Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial.J Invest Dermatol2023https://conductscience.org/library/papers/37331616PubMed
328652111Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro.J Invest Dermatol2017https://conductscience.org/library/papers/28652111PubMed
423190767The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum.Clin Exp Rheumatol2013https://conductscience.org/library/papers/23190767PubMed
512529736Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.Thromb Haemost2002https://conductscience.org/library/papers/12529736PubMed
621482889Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study.Arch Dermatol2011https://conductscience.org/library/papers/21482889PubMed
730657093Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series.Adv Rheumatol2018https://conductscience.org/library/papers/30657093PubMed
833675790Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness.J Invest Dermatol2021https://conductscience.org/library/papers/33675790PubMed
924506658Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.Mod Rheumatol2014https://conductscience.org/library/papers/24506658PubMed
1029741608JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.Brain2018https://conductscience.org/library/papers/29741608PubMed
1130508240Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?Br J Dermatol2018https://conductscience.org/library/papers/30508240PubMed
1236578492Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.Front Immunol2022https://conductscience.org/library/papers/36578492PubMed
1331279813Dermatomyositis: Diagnosis and treatment.J Am Acad Dermatol2020https://conductscience.org/library/papers/31279813PubMed
1436622138Current concepts and advances in dermatomyositis: a dermatological perspective.Clin Exp Rheumatol2023https://conductscience.org/library/papers/36622138PubMed
1535490744Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.J Invest Dermatol2022https://conductscience.org/library/papers/35490744PubMed
1623680200Methotrexate for the treatment of cutaneous dermatomyositis.J Am Acad Dermatol2013https://conductscience.org/library/papers/23680200PubMed
1721981743Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions.Clin Exp Dermatol2012https://conductscience.org/library/papers/21981743PubMed
1824856183Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.Bioorg Med Chem2014https://conductscience.org/library/papers/24856183PubMed
1917576943A pilot trial of rituximab in the treatment of patients with dermatomyositis.Arch Dermatol2007https://conductscience.org/library/papers/17576943PubMed
2032057402The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review.Semin Arthritis Rheum2020https://conductscience.org/library/papers/32057402PubMed

See all 81 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
41910912Association of malnutrition with in-hospital outcomes among patients hospitalized with dermatomyositis or polymyositis.Clin Rheumatol2026https://conductscience.org/library/papers/41910912PubMed
41768519Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Arch Intern Med Res2026https://conductscience.org/library/papers/41768519PubMed
41545853Dermatomyositis and Polymyositis: Are Both Ends of a Same Spectrum?J Cosmet Dermatol2026https://conductscience.org/library/papers/41545853PubMed
41441445An Update on Dermatomyositis and Related Inflammatory Myopathies: Cutaneous Clues, Skeletal Muscle Involvement, and Advances in Pathogenesis and Treatment.Muscles2025https://conductscience.org/library/papers/41441445PubMed
40770118Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.Semin Immunopathol2025https://conductscience.org/library/papers/40770118PubMed
40227497The Importance and Challenges of Early Diagnosis of Paraneoplastic Skin Syndromes in Cancer Detection-A Review.Cancers (Basel)2025https://conductscience.org/library/papers/40227497PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39343752

GET https://conductscience.org/api/papers/v1/39343752/references?page=2